Treatment Options for Multiple Myeloma Patients Who Have Relapsed From or Are Refractory to Multiple Therapies

Access Activity

Overview / Abstract:

ACTIVITY DESCRIPTION
Multiple myeloma (MM) patients inevitably experience relapse or develop resistance to initial multidrug combinations in spite of high complete response rates, but a growing number of these patients are benefiting from the availability of several novel agents. Patients who have not responded satisfactorily to the three main classes of drugs currently used to treat myeloma (proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies)—a group known as triple class refractory—potentially stand to benefit from the growing list of available novel agents. To improve the prognosis for these patients, clinicians must be able to adjust their current therapeutic strategies based on the availability of these newer agents. Additionally, immunotherapy is emerging as a viable treatment strategy and may expand the myeloma armamentarium.

This CME/CNE-certified webinar will help oncology health care providers deliver the best possible care to patients with MM and keep up with the rapid advancements in treatments relating to current and new agents in the relapsed/refractory setting.

Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the options available to patients who have relapsed from or are resistant to multiple prior therapies
- Evaluate recent clinical advances in the use of immunotherapies, including antibody-drug conjugates and CAR T-cell therapy, and their potential implications for clinical practice in patients with relapsed refractory multiple myeloma

Expiration

Sep 30, 2021

Discipline(s)

Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME

Format

Webinar / Webcast / Video

Credits / Hours

Physician Accreditation Statement This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy, the Multiple Myeloma Research Foundation, and RedMedEd. Purdue University College of Pharmacy is accredited by the ACCME to provide continuing medical education for physicians. Designation Statement Purdue University College of Pharmacy designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. ABIM MOC Part II Points Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. CNE Contact Hours Accreditation Statement Purdue University Continuing Nursing Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. Designation Statement This activity is approved for 1.0 Nursing Contact Hour.

Accreditation

ACCME, ANCC, ABIM MOC

Presenters / Authors / Faculty

Ajai Chari, MD
Professor of Medicine
Director of Clinical Research, Multiple Myeloma Program
Icahn School of Medicine at Mount Sinai
New York, New York

Paul G. Richardson, MD
R. J. Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader and Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Activity Specialities / Related Topics

Oncology / Cancer / Radiation Therapy, Hematology, Education / Teaching

Sponsors / Supporters / Grant Providers

This activity is supported by educational grants from Bristol Myers Squibb; Karyopharm Therapeutics, Inc.; Oncopeptides; and Sanofi Genzyme.

Keywords / Search Terms

RedMedEd, MMRF, MM, multiple myeloma, multiple myeloma research foundation, Purdue University, relapse, multidrug, Free CME, free, hematologist-oncologist, medical oncologist, oncology, cancer, hematology, cancer, nurse, novel agents, combinations, relapsed/refractory, current, therapeutic, strategies, triple class refractory, treat myeloma, patients, response rate, resistance, resistant, CAR T-cell therapy, CAR T,

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map